Comparative Pharmacology
Head-to-head clinical analysis: EPOGEN PROCRIT versus VAFSEO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPOGEN PROCRIT versus VAFSEO.
EPOGEN/PROCRIT vs VAFSEO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythropoiesis-stimulating agent that binds to and activates the erythropoietin receptor on erythroid progenitor cells, stimulating proliferation and differentiation into mature red blood cells.
VAFSEO (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It stabilizes HIF-α, leading to increased transcription of genes involved in erythropoiesis, including erythropoietin, enhancing red blood cell production.
50-100 units/kg intravenously or subcutaneously three times weekly. Initial dose 50 units/kg three times weekly; adjust to maintain hemoglobin target (usually 10-12 g/dL).
Oral: 20 mg three times weekly for 24 weeks.
None Documented
None Documented
Terminal half-life: ~4-13 hours in healthy subjects; prolonged to 13-28 hours in chronic kidney disease or on dialysis (due to reduced clearance).
Terminal half-life is approximately 20-30 hours, supporting once-daily dosing.
Primarily hepatic metabolism; ~10% excreted unchanged in urine. Fecal elimination negligible.
Primarily fecal (approximately 81%) and renal (~17%) as unchanged drug and metabolites.
Category C
Category C
Erythropoiesis-Stimulating Agent
Erythropoiesis-Stimulating Agent